synthesis is not required for the TPA induced increase in mRNAs recognized by λB3 and λB10. Addition of a protein synthesis inhibitor alone leads to marked accumulation of mRNA recognized by λB3. Analysis of genomic organization indicates that λB10 contains sequences belonging to a repeated gene family or a family of closely related genes whereas sequences present in λB3 may correspond to a unique gene. The expression patterns of mRNAs recognized by λB3 and λB10 suggest that they may be associated with early phases of the genetic programme for growth, although a specific function in this programme remains to be shown.

TUMOUR PROMOTER PMA REVRSES THE ORDER IN WHICH CELLS ENTER MITOSIS

R.M.Böhmer

Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Victoria, Australia 3050.

Tumour promoting phorbol ester derivatives are known to stimulate as well as inhibit the cell cycle traverse of many kinds of cells, but it is not known whether or how these effects are related to tumour promotion. It is shown here that the potency of the phorbol diester PMA to cause a delay of cell division in human fibroblasts depends on the cycle status at the beginning of exposure to the PMA. Cells which become exposed while they are in an early stage of the cycle are less effectively delayed and reach mitosis earlier than those for which exposure begins at a later stage of the cycle. Thus PMA actually reverses the cycle-age distribution and the order of cell division within a normally growing population. Since growth regulation in self-renewing tissues is dependent on intercellular communication which is likely to be effected by the relative cell cycle positions of neighbouring cells, this reversal of cell cycle age may cause a disturbance of growth regulation, leading to hyperplasia and tumourigenesis.

FUCOSE AND SIALIC ACID AS PROGNOSTIC INDEXES IN PATIENTS WITH BREAST CANCER

Otilia Bojan and Ion Kiricuta

Oncological Institute, Cluj-Napoca, Romania

Fucose and sialic acid were determined in sera of 700 patients with breast cancer in various stages of evolution and compared with 150 patients with benign lesions of the breast and 80 healthy women, respectively. Both parameters levels increased together with tumour volume enhancement. The most relevant results were found for fucose which was found significantly increased starting with stage I, its values being more frequently elevated and with higher magnitude in cases when homolateral lymph nodes were invaded. In patients with recurrences and/or metastases higher levels of fucose were found in 96% of cases and the modifications occurred at about 2 to 3 months before any clinical or radiological evidence of recurrences or metastases. Our results revealed that fucose is a better marker than sialic acid both in tumour volume estimation and disease expansion as well as in prognosis of breast cancer.

TRISOMY 13 - A RARE ACQUIRED CHROMOSOMAL ABERRATION

G.H.Borgström(1) and S.Pakkala(2)

(1)Department of Medical Genetics and (2)Transplantation Laboratory, University of Helsinki, Helsinki, Finland.

Trisomy 13 occurring as the sole aberration in an acquired clone was seen in three patients, two males and one female, aged 77, 44 and 53 respectively, in over 15,000 patients studied because of malignant disorders. All three patients had acute non-lymphocytic leukaemia (ANLL). One patient had had RAEB-T diagnosed previously, two others had findings suggesting that their leukaemia had evolved through a myelodysplastic phase. ANLL types were M2, M2 and M2/M4 respectively. Haematologically, the patients were rather different (Hb range : 92 to 165 g/l; WBC : 3.1 to 250 x 10^9; platelets : 31 to 255 x 10^9/l.

Cells with trisomy 13 as well as normal cells were found in the bone marrow of all patients. Peripheral blood lymphocytes had a normal karyotype. One patient had two additional clones in the bone marrow : 47,XX,+13,7q- and 48,XX,+13,+21.

Trisomy 13 thus is a rare acquired aberration which, based on these three patients, occurs in ANLL with a preceding myelodysplastic phase.

GENETIC ACTIVITY OF CHLORINATED ETHANES

G.Bronzetti, A. Galli, R. Vellosi, F.Rossi, E.Morichetti and R.Del Carratore

Istituto di Mutagenesi e Differenziamento del CNR, Via Svezia 10, 56100 Pisa, Italy

This work, sponsored by Associazione Italiana Ricerca sul Cancro (AIRC), is a part of an interdisciplinary program on